EnVivo is developing EVP-6308, a phosphodiesterase (PDE) inhibitor that is novel, highly potent and highly selective. To date, EVP-6308 has demonstrated efficacy in preclinical schizophrenia animal models that, in the past, have been predictive of clinical benefit in patients. This activity may be potentially useful to treat positive, negative, and cognitive symptoms in patients with acute and chronic schizophrenia and represents a completely new treatment approach.

EnVivo initiated a Phase 1 study of EVP-6308 in early 2012.